This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Enobosarm
DrugBank Accession Number
DB12078
Background

Enobosarm has been used in trials studying the treatment of Stress Urinary Incontinence and Triple Negative Breast Cancer.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 389.328
Monoisotopic: 389.098725944
Chemical Formula
C19H14F3N3O3
Synonyms
  • Enobosarm
  • Énobosarm
  • Enobosarmum
  • Ostarine
External IDs
  • GTX 024
  • GTX-024
  • MK 2866
  • MK-2866

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as trifluoromethylbenzenes. These are organofluorine compounds that contain a benzene ring substituted with one or more trifluoromethyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Trifluoromethylbenzenes
Direct Parent
Trifluoromethylbenzenes
Alternative Parents
Anilides / Phenoxy compounds / Phenol ethers / N-arylamides / Benzonitriles / Alkyl aryl ethers / Tertiary alcohols / Secondary carboxylic acid amides / Nitriles / Organopnictogen compounds
show 5 more
Substituents
Alcohol / Alkyl aryl ether / Alkyl fluoride / Alkyl halide / Anilide / Aromatic homomonocyclic compound / Benzonitrile / Carbonitrile / Carbonyl group / Carboxamide group
show 18 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
O3571H3R8N
CAS number
841205-47-8
InChI Key
JNGVJMBLXIUVRD-SFHVURJKSA-N
InChI
InChI=1S/C19H14F3N3O3/c1-18(27,11-28-15-6-2-12(9-23)3-7-15)17(26)25-14-5-4-13(10-24)16(8-14)19(20,21)22/h2-8,27H,11H2,1H3,(H,25,26)/t18-/m0/s1
IUPAC Name
(2S)-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
SMILES
C[C@](O)(COC1=CC=C(C=C1)C#N)C(=O)NC1=CC=C(C#N)C(=C1)C(F)(F)F

References

General References
Not Available
KEGG Drug
D10221
PubChem Compound
11326715
PubChem Substance
347828384
ChemSpider
9501667
RxNav
2168587
ChEMBL
CHEMBL1738889
ZINC
ZINC000035793636
PDBe Ligand
RLJ
Wikipedia
Enobosarm
PDB Entries
3rlj

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentMuscular Disorders, Atrophic / Non-Small Cell Lung Carcinoma (NSCLC)2
3RecruitingTreatmentMetastatic Breast Cancer2
2Active Not RecruitingTreatmentAndrogen Receptor Positive / Estrogen Receptor Negative / HER2/Neu Negative / Metastatic Triple-Negative Breast Carcinoma / Progesterone Receptor Negative / Stage IV Breast Cancer AJCC v6 and v71
2CompletedSupportive CareCachectic1
2CompletedTreatmentER+ and AR+ Breast Cancer2
2CompletedTreatmentMetastatic Breast Cancer1
2CompletedTreatmentStress Urinary Incontinence (SUI)2
2TerminatedTreatmentStress Urinary Incontinence (SUI)2
2TerminatedTreatmentTriple Negative Breast Cancer1
1CompletedTreatmentMammographic Density1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00563 mg/mLALOGPS
logP2.82ALOGPS
logP3.27Chemaxon
logS-4.8ALOGPS
pKa (Strongest Acidic)11.95Chemaxon
pKa (Strongest Basic)-4Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area106.14 Å2Chemaxon
Rotatable Bond Count6Chemaxon
Refractivity95.05 m3·mol-1Chemaxon
Polarizability35.87 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at October 20, 2016 21:18 / Updated at February 21, 2021 18:53